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Abstract
Background: Hepatitis B virus infection remains an important global health concern despite the availability of safe and
effective prophylactic vaccines. Limitations to these vaccines include requirement for refrigeration and three immunizations
thereby restricting use in the developing world. A new nasal hepatitis B vaccine composed of recombinant hepatitis B
surface antigen (HBsAg) in a novel nanoemulsion (NE) adjuvant (HBsAg-NE) could be effective with fewer administrations.
Methodology and Principal Findings: Physical characterization indicated that HBsAg-NE consists of uniform lipid droplets
(349+/217 nm) associated with HBsAg through electrostatic and hydrophobic interactions. Immunogenicity of HBsAg-NE
vaccine was evaluated in mice, rats and guinea pigs. Animals immunized intranasally developed robust and sustained
systemic IgG, mucosal IgA and strong antigen-specific cellular immune responses. Serum IgG reached $10
6 titers and was
comparable to intramuscular vaccination with alum-adjuvanted vaccine (HBsAg-Alu). Normalization showed that HBsAg-NE
vaccination correlates with a protective immunity equivalent or greater than 1000 IU/ml. Th1 polarized immune response
was indicated by IFN-c and TNF-a cytokine production and elevated levels of IgG2 subclass of HBsAg-specific antibodies.
The vaccine retains full immunogenicity for a year at 4uC, 6 months at 25uC and 6 weeks at 40uC. Comprehensive pre-clinical
toxicology evaluation demonstrated that HBsAg-NE vaccine is safe and well tolerated in multiple animal models.
Conclusions: Our results suggest that needle-free nasal immunization with HBsAg-NE could be a safe and effective hepatitis
B vaccine, or provide an alternative booster administration for the parenteral hepatitis B vaccines. This vaccine induces a Th1
associated cellular immunity and also may provide therapeutic benefit to patients with chronic hepatitis B infection who
lack cellular immune responses to adequately control viral replication. Long-term stability of this vaccine formulation at
elevated temperatures suggests a direct advantage in the field, since potential excursions from cold chain maintenance
could be tolerated without a loss in therapeutic efficacy.
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Introduction
Infection with hepatitis B virus (HBV) remains an important
global health concern, despite the availability of multiple
prophylactic vaccines. The World Health Organization (WHO)
estimates that more than 2 billion persons have been infected with
the virus. The current prophylactic vaccines require a regimen of
three intramuscular (i.m.) injections, have a 10%215% non-
responders rate, and are ineffective for limiting HBV replication in
chronic carriers [1,2,3]. Large scale vaccination programs are also
limited in developing populations due to compliance issues
secondary to the three dose vaccination schedule, the requirement
for cold storage and the availability of sterile needles [4,5]. This
has limited the use of hepatitis B vaccine in these populations and
is partly responsible for 8%210% of the population in areas of
Africa, Asia and South America being chronically infected with
HBV [6]. Chronic HBV infection increases the risk of developing
liver cirrhosis, hepatocellular carcinoma and other associated
complications leading to increased mortality [7]. This suggests the
need for a new strategy on hepatitis B vaccination for the
developing world.
Hepatitis B surface antigen (HBsAg) is a major structural
protein of HBV and is a protective immunogen in experimental
animals and in humans [8,9,10]. The hepatitis B surface (HBs)
proteins are synthesized as large (L), medium (M) and small (S)
envelope sub-units, which self assemble into virus-like lipid-
anchored particles (about 22 nm in size) [11,12]. The majority
of commercially available recombinant HBsAg vaccines (including
Recombivax HB; Merck, and Engerix-B; GSK) consist of yeast
derived HBs-S antigen particles adsorbed to an aluminum salt
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is considered safe, some adverse effects have been reported
[14,15]. Further, alum has been shown to elicit predominantly a
Th2 polarization of immune response, which is associated with
cellular immunity that is ineffective at producing CD8 responses to
virally infected cells [16]. Since cellular immunity is essential for an
efficient response against some infections and elimination of some
viral pathogens [17], it would be desirable to develop anti-viral
vaccine(s) capable of inducing cell-mediated immunity, in addition
to a robust and durable antibody response [17,18]. Currently
available hepatitis B vaccines have comparable thermo-stability
profiles requiring unbroken cold chain storage (between 2uC and
8uC) in order to retain potency [19,20]. The higher costs
associated with guaranteed cold chain, from point of manufacture
to point of use, also contribute to the inaccessibility of these
vaccines. Thus, an efficacious vaccine requiring fewer injections
and a less stringent cold storage requirement would directly benefit
underserved populations.
Mucosal immunization is an attractive alternative to parenteral
vaccines because it can produce both systemic and mucosal
immunity and avoids the need for sterile needles [21,22].
However, development of mucosal vaccines remains limited by
lack of effective mucosal adjuvants [23,24]. Studies have evaluated
several potential mucosal adjuvants for hepatitis B vaccines
including recombinant cholera toxin (CT) [25], lipid microparti-
cles [26], CpG oligonucleotides [27,28], cationic particles [29],
PLG microspheres [30] or hepatitis B core antigen (HBcAg)
[31,32,33]. CT has been limited from use in humans due to its
potential to cause CNS inflammation. Unfortunately, a CpG-
adjuvanted injectable hepatitis B vaccine was recently placed on
clinical hold due to inflammatory issues in a patient, further calling
into question the safety of pro-inflammatory adjuvants. No other
adjuvant, with the exception of HBcAg, has even been tested in
clinical trials [34,35,36]. This underlines the need for new non-
toxic mucosal adjuvants.
This study evaluates the formulation, immunogenicity, thermal
stability and pre-clinical safety of a novel mucosal, needle-free
hepatitis B vaccine. These vaccine formulations are composed of
recombinant HBsAg using nanoemulsions (NEs) (NanoBio Cor-
poration, Ann Arbor, MI) as mucosal adjuvants. NEs are
nanoscale (,400 nm) emulsions formulated with surfactants,
distilled water, refined soybean oil and ethanol as a solvent.
Initially developed as broad-spectrum antimicrobial agents
[37,38,39], NEs proved effective as mucosal adjuvants for a range
of antigens from whole influenza and vaccinia viruses to
recombinant anthrax protective antigen and HIV gp120
[40,41,42,43]. In animals, these experimental NE-based vaccines
do not produce local inflammation as is observed with alum-based
vaccines [15]. However, these formulations are effective in
inducing Th1 biased immune response and cellular immunity
[41], and remain stable for at least three years at 25uC (Hamouda
T., NanoBio, personal communication). These inherent advan-
tages of NE provided a rationale for evaluating it as a mucosal
adjuvant in a candidate nasal vaccine for prevention of hepatitis B
infection.
Results
Characterization of vaccine formulation
The candidate hepatitis B vaccine was formulated from two
components; recombinant HBsAg and NE (HBsAg-NE). The
formulation was characterized by evaluating the stability of its
components, as well as the physical interaction of the antigen with
NE.
To characterize NE stability, emulsion droplet size was analyzed
in a broad range of concentrations (1% to 40%) both alone and
mixed with either low (0.5 mg/ml) or high (2.5 mg/ml) concen-
trations of HBsAg. The effect of temperature on the mixing of
antigen and NE of was evaluated by incubating each of the
formulations at either 4uC, 25uC, or 40uC for 72 hours. The lipid
droplet size was stable and uniform in both concentrations of
antigen (the average size for all conditions calculated as
349617 nm), and droplet size of the mixture was not altered by
either temperature or NE concentration (Table 1).
HBsAg integrity in the emulsion was evaluated using SDS-PAGE
and Western blot (Figures 1A and B). NE also did not interfere
with the electrophoresis or immunoblotting procedures. After
treatment with SDS, HBsAg protein migrated as a band that
corresponded to HBsAg monomer (Mw<24 kDa) with a minor
fraction at twice this molecular weight representing dimer, and this
pattern was not altered by prior mixing in NE. In addition,
antigenic recognition was retained in HBsAg mixed in NE as
identified in Western Blots using a polyclonal goat antiserum raised
to native HBsAg (Figure 1B). No degradation products of HBsAg
were detected in either analysis and was no significant aggregation
appeared to occur during mixing or incubation with NE.
The surface charge of the vaccine formulation was determined
by measuring the zeta potential and was compared to NE and
HBsAg solutions with deionized water and PBS buffer used as
diluents. In either diluent, HBsAg had negative zeta potential as
has been previously reported in literature (Figure 2A) [44]. In
contrast, there was a decrease in the positive zeta potential of the
NE after mixing with the HBsAg. This suggests an electrostatic
association between the negatively charged HBsAg particles and
Table 1. Consistency of nanoemulsion particle size.
Particle Size
Temperature Condition (uC)
Sample description Fresh 4 25 40
1% W805EC 355 (+/2130) 385 (+/2141) 327 (+/2168) 353 (+/2201)
20% W805EC 368 (+/2255) 328 (+/2159) 350 (+/2166) 337 (+/2166)
40% W805EC 331 (+/2154) 373 (+/2221) 322 (+/2178) 340 (+/2153)
20% W805EC+0.5 mg/ml HBsAg 373 (+/2229) 325 (+/2142) 354 (+/2193) 347 (+/2200)
20% W805EC+2.5 mg/ml HBsAg 341 (+/2143) 348 (+/2177) 361 (+/2227) 347 (+/2232)
Average particle size 349 (+/217); Mean (+/2SD).
doi:10.1371/journal.pone.0002954.t001
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emulsion was more pronounced when the HBsAg/NE formulation
was made with deionized water as compared to buffers such as
PBS (Figure 2).
The interaction of HBsAg with NE was further examined using
laser diffraction particle sizing and isothermal titration calorimetry
(ITC). Two independent and differently sized peaks for NE and
HBsAg were observed before mixing, however after formulation
only a single peak was detected with a dynamic diameter of
,300 nm (Figures 2B, C, and D and Table 1). The absence
of two separate peaks again indicated an association between the
lipid phase and HBsAg protein, and suggested that no significant
fraction of the antigen remained independent from the lipid in the
aqueous phase of NE. Thermodynamic analysis of the interaction
between the HBsAg and the NE using ITC showed a spontaneous
exothermic reaction with a calculated change in heat capacity of
binding (DCp) of 21.44 indicating an energetically favorable
interaction (Figure 2E).
Optimization the immunogenicity of the nasal HBsAg-NE
vaccine
Immunogenicity of the HBsAg-NE vaccine formulation was
optimized by conducting in vivo adjuvant and antigen dose
escalation studies. To optimize the NE concentration for the
vaccine, CD-1 mice were intranasally (i.n.) immunized with 20 mg
of HBsAg mixed with a range of NE concentrations from 5% to
40% using antigen in PBS as a control. After a single
immunization with 20 mg of HBsAg in either 10%, 20% or 40%
NE, similar end-point serum anti-HBsAg IgG titers averaging over
10
4 were achieved (Figure 3A). In contrast, significantly lower
serum titers (,10
2) were generated after immunization with 5%
NE and low, inconsistent antibody responses were detected in
mice nasally vaccinated with HBsAg in PBS (Figure 3A). Booster
immunization at six weeks caused the serum anti-HBsAg IgG titers
to increase over 10 fold in all groups except in the animal
immunized with HBsAg in PBS where no effect was observed. The
highest anti-HBsAg antibody endpoint titers, exceeded 10
6 at 6 to
8 weeks after boost, were achieved when the animals were
vaccinated with either 20% or 40% NE. The HBsAg-NE vaccine
also produced persistent antibody responses with serum anti-
HBsAg IgG titers of 10
4–10
5 at 6 months after initial vaccination
regardless of the concentration of NE used for vaccination. Thus,
the lowest optimal NE concentration was determined to be 20%.
To optimize the antigen concentration in the NE vaccine, mice
were i.n. immunized with 1 mg, 5 mg2 0mg and 40 mg of HBsAg
mixed with 20% NE (Figure 3B). After a single vaccination anti
IgG HBsAg antibody responses showed a dose dependent
relationship with highest titers in the 20 mg HBsAg-NE group
and significantly weaker antibody responses in mice vaccinated
with 1 mg of HBsAg. After a second immunization at six weeks, the
anti-HBsAg IgG titers increased approximately 10 fold exceeding
10
4, except in animals immunized with 1 mg HBsAg in NE.
Intranasal immunizations with equivalent amounts of HBsAg
mixed in PBS again produced only sporadic and weak antibody
responses with titers less than 10
2 (data not shown). This indicated
that 20 mg of HBsAg appeared in the optimal antigen dose.
Immunogenicity of HBsAg-NE immunization
The humoral and cell-mediated immune responses to the
optimized HBsAg-NE vaccine were characterized in vivo in mice.
Intranasal vaccination with either 20 mg HBsAg-20% NE or i.m.
injection of 20 mg HBsAg-Alu resulted in comparable, high levels
of anti-HBsAg serum IgG antibodies reaching 10
5 to 10
6 titers
within 8 weeks after primary vaccination (Figure 4A). HBsAg-Alu
induced a slightly more rapid response, producing higher IgG
titers than HBsAg-NE at 2 weeks after primary vaccination (p
value,0.05), but this difference disappeared after a single booster
immunization. Both HBsAg-NE and HBsAg-Alu vaccines pro-
duced equivalent, durable immune responses with serum anti-
HBsAg IgG end point titers of 10
4 to 10
5 being maintained up to
6 months after vaccination. Nasal vaccination with HBsAg-NE
elicited serum titers in mice that when normalized with
standardized human anti-HBsAg serum indicated an antibody
index $1000 IU/ml (data not shown). This index is compatible
with protective immunity in humans.
Analysis of serum IgG anti-HBsAg avidity at 23 weeks indicated
significantly higher antibody avidity in HBsAg-NE immunized
animals as compared to IgG from HBsAg-Alu vaccinated mice (p
value=0.034)( Figure 4B). While the overall titers were equiva-
lent, analysis of serum IgG subclass indicated that i.n. HBsAg-NE
vaccination produced anti-HBsAg IgG with a prevalence of IgG2b
(and IgG2a) over IgG1 subclass antibodies, while consistent with
previous reports [46,47] the HBsAg-Alu vaccine produced mainly
IgG1 subclass antibodies (Figure 4C). This suggests a Th1
response to the NE-based vaccine vs. the traditional Th2 response
associated with alum. Immunization with HBsAg-NE composed of
adw serotype surface antigen also produced cross-reacting IgG
antibodies against the heterologous ayw serotype (data not shown).
Mucosal immune responses were characterized in bronchioal-
veolar lavage (BAL) fluid of immunized animals. HBsAg specific
IgA and IgG antibodies were detected in BAL samples obtained at
the conclusion of the study (23 weeks after initial immunization)
from mice immunized intranasally with HBsAg-NE (Figure 5A
Figure 1. Stability of HBsAg. Silver stained SDS-PAGE: Analysis
of freshly prepared vs. 72 hour incubated HBs antigen mixed with 20%
NE (A). Conditions of the incubation are specified above the gel. HBsAg
monomer and dimer are indicated with arrows at 24 kDa and 48 kDa
bands. Western blot: The protein configuration is identical to as
described for SDS-PAGE (B). HBsAg is detected using a polyclonal anti-
HBsAg antibody for all incubation conditions.
doi:10.1371/journal.pone.0002954.g001
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levels of IgA anti-HBsAg (data not shown). No anti-HBsAg
antibodies were detected in BALs or serum in mice immunized
with antigen administered in PBS or in intramuscularly immu-
nized mice despite high serum titers.
HBsAg specific cellular responses were characterized in
splenocytes of immunized outbred CD-1 mice obtained at
18 weeks after last immunization. The cells were stimulated with
HBsAg and then evaluated for specific cytokine production
(Figure 5C). The cytokine expression pattern included high
production of the Th1-type cytokines IFN-c and TNF-a (ranging
from 5 to 40 fold) and lower increases (#2 fold) in the expression
of Th2-type cytokines IL-4, IL-5 and IL-10. This pattern of
expression suggested a Th1 bias of cell-mediated response.
The serum IgG response elicited by HBsAg-NE vaccine was
also studied in two alternative rodent species to ensure that the
immunization effect was not species specific. Rats and guinea pigs
were immunized with 5 mg and 20 mg doses of HBsAg mixed with
20% NE (Figure 6). After a single vaccination, animals showed a
dose dependent response with the highest IgG antibody titers in
the 20 mg HBsAg-NE group. After a second administration at five
weeks, the anti-HBsAg IgG titers increased up to 100 and 1000
fold surpassing 10
5 titers in both species. Thus, the HBsAg-NE
vaccine appeared immunogenic in all three animal species tested.
Thermal Stability of HBsAg-NE vaccine
The optimized formulation of HBsAg-NE was evaluated for
thermal stability at three test temperatures. The vaccine product
was mixed to contain 2.5 mg/ml HBsAg in 20% NE (to obtain a
single dose of 20 mg of antigen in a final volume of 8 ml) and
aliquoted into capped glass vials for storage at 462uC, 2562uCo r
4062uC. At 6 weeks, 3 months, 6 months and a year after the
start of the stability study aliquots of the formulation were
evaluated for physical stability in vitro and immunogenicity in vivo.
HBsAg stability in vaccine samples was analyzed by SDS-PAGE
with silver staining and antigenicity evaluated with Western blots
(Figure 7) with the stored samples compared to freshly mixed
vaccine at each time point. The protein stains and Western Blots
of HBsAg at 6 weeks and 3 months were not different from fresh
material and there were no low molecular weight degradation
products appreciable at these or any later time points (Figure 7A
and B). After 6 months of storage (Figure 7B), however, the
major HBsAg band was not detectable in the 40uC by silver
staining or immunoblotting, whereas both 4uC and 25uC stored
products were still comparable to freshly mixed vaccine. After
1 year of storage (Figure 7C), the 25uC sample was also
degraded, while the 4uC stored formulation was intact and
comparable to freshly mixed vaccine. The stability of the NE also
Figure 2. HBsAg interaction with NE droplets. Zeta potential:
(A) The zeta potential was measured for HBsAg (2.5 mg/ml), 20% NE
and mixture of HBsAg with NE (HBsAg-NE) in water and PBS. Surface
charge is reported in mV units. Particle sizing: Size distribution was
measured using a laser diffraction particle-sizer. Analysis of HBsAg alone
(B), NE alone (C), and NE with 10 mg/ml of HBsAg (D). Data was
processed and analyzed using Fraunhofer optical modeling and
number weighted averaging (number %). Single population intensity
peaks indicate monodisperse populations of HBsAg (28 nm), NE
(349 nm), and HBsAg-NE (335 nm). Calorimetric titration of HBsAg
with NE: 25 injections of 1% NE (10 ml/injection) were introduced into
a sample cell containing HBsAg (600 mg/ml in PBS) at 30uC. The upper
panel shows differences between the sample and reference cell
containing PBS. The lower panel shows enthalpy per injection of NE
injected versus injection number. An exothermic reaction was
measured following the addition of nanoemulsion to an antigen
solution. Addition of nanoemulsion to the antigen solution became less
energetic as the total concentration of nanoemulsion increased,
suggesting that the antigen was being depleted. DCp was calculated
to be 21.44 [77].
doi:10.1371/journal.pone.0002954.g002
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mean diameter (6SD) of freshly mixed HBsAg-NE samples was
0.32360.016 m, and there were no significant differences between
NE particle sizes of fresh and stored HBsAg-NE samples at any
temperature or time point.
Immunogenicity of the vaccine in CD-1 mice was tested at each
time point and storage temperature. Mice were immunized then
boosted at six weeks post-vaccination, and anti-HBsAg serum IgG
responses were determined at 2, 3, 5, 8, 10 and 12 weeks after
primary vaccination. There were no significant differences in
serum IgG titers elicited by HBsAg-NE vaccine stored at any
temperature up to 3 months (Figure 8A and B). At 6 months of
storage, HBsAg-NE stored at 40uC could elicit and boost HBsAg-
specific antibodies, but at a significantly decreased titer when
compared to freshly mixed vaccine, while 4uC and 25uC stored
vaccines retained complete immunogenicity (Figure 8C). After
1 year of storage, 25uC stored HBsAg-NE elicited decreased
serum IgG while the 4uC and 25uC stored vaccines again retained
complete immunogenicity (Figure 8D). This indicated that the
vaccine retained immunogenicity for 3 months at 40uC and
6 months at 25uC.
Evaluation of the safety of NE adjuvant and HBsAg-NE
vaccine
Comprehensive evaluation of acute and (sub) chronic toxic
effect of NE and HBsAg-NE formulations was performed in
rodent models and in dogs. Multiple intranasal dose studies
(ranging from 2 to 7 total doses as shown in Table 2) for NE
adjuvant or HBsAg-NE were conducted. No statistically significant
changes in subcutaneous temperature or body weight were
observed in these species as compared to non-treated control
groups (data not shown). Likewise, no observable changes in
activity or appetite were noted throughout the study. Hematolog-
ical and serum biochemical results in rats, guinea pigs, and dogs
were within normal physiological range (Table 2). No lesions
were reported in highly perfused organs including the olfactory
bulb and frontal lobe of the brain. Cytotoxicity was not observed
in nasal epithelium and other exposed tissues. The only
histological lesion noted was the accumulation of amorphous
material that sometimes contained cellular debris from sloughed
nasal epithelial cells. None of the lesions were of clinical
significance (Table 2 and Figure 9). For further analysis, serum
was collected in mice 24 hours following i.n. vaccination with NE-
HBsAg and was evaluated for the presence of IL-1a. IL-1b, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, G-
CSF, GM-CSF, IFN-c, IP-10, KC, MCP-1, MIP-1a, RANTES,
TNF-a using a LINCOplexH Mouse Cytokine/Chemokine kit.
Serum concentrations of IL-6 significantly exceed those of the
non-treated controls (933 pg/ml NE-HBsAg vs. 174 pg/ml for
PBS control [p value=0.053]). The production of IL-6, however,
occurs in the absence of neutrophilic, macrophagic, or other
inflammatory cellular infiltration in directly exposed nasal
epithelium (Figure 9). Overall, both NE and HBsAg-NE were
safe and well tolerated by all animal species tested. Approximately
5% of mice developed nasal obstruction with the emulsion, but this
Figure 3. Development of IgG response in serum. Effect of NE adjuvant: Mice were immunized intranasally with HBsAg-NE consisting of
20 mg of HBsAg mixed with 0% to 40% concentrations of NE (A). Significant statistical difference with p value,0.05 was observed between all HBsAg-
NE formulations and HBsAg-PBS vaccine. Antigen dose escalation: Mice were immunized intranasally with 1 mgt o4 0mg HBsAg mixed with 20%
NE (B). A significant statistical difference with p value,0.05 was observed between all 5 mgt o4 0mg HBsAg-NE formulations and 1 mg HBsAg-NE
vaccine. Serum anti-HBsAg IgG antibody concentrations are presented as mean of endpoint titers in individual sera +/2 SEM. * indicates a statistical
difference (p value,0.05) in the anti-HBsAg IgG titers. Arrows indicate vaccine administration.
doi:10.1371/journal.pone.0002954.g003
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the unique nasal anatomy of the mouse.
Discussion
The commercial hepatitis B vaccines are a remarkable triumph
in disease prevention. As one of the first recombinant biological
products used as a vaccine, these formulations have a 20 year
record of efficacy in preventing hepatitis B and have excellent
safety with local reactions from the alum adjuvant being the
predominant adverse event [1,2,48,49]. However, hepatitis B
remains a significant health issue, especially in the developing
world. While efforts of local producers have greatly reduced the
cost of the vaccine, the requirement for sterile needles and syringes
for administration, and a refrigerated cold chain have conspired to
prevent vaccination of many at-risk populations. Because of these
issues there is an ongoing interest in producing needle-free and
thermally stable hepatitis B vaccines with similar safety and
efficacy to the current commercial alum-based vaccines
[19,20,50].
This study documents the immunogenicity of a novel, mucosal
hepatitis B vaccine that is based on a mixture of recombinant
HBsAg and nanoemulsion adjuvant. A single nasal immunization
of the HBsAg-NE mixture produces a rapid induction of serum
anti-HBsAg IgG, which is comparable to that achieved with i.m.
vaccination using aluminum salt-based vaccine. Serum IgG
responses could be boosted and the titers persisted for the
23 weeks duration of these studies. Normalization carried out by
comparison to a standardized human anti-HBsAg serum indicated
that anti-HBsAg antibody titers in mice immunized with a nasal
HBsAg-NE vaccine corresponded to a greater than 1,000 mIU/ml
HBsAg IgG concentration in humans which are considered to be
seroprotective against HBV infection [2,51]. There was also
evidence suggesting affinity maturation in the antibody response as
serum IgG from animals vaccinated with HBsAg-NE indicated
that their avidity matured over time to achieve higher values at
23 weeks than at 5 weeks after vaccination (data not shown). This
is important since functional antibody maturation is considered a
significant correlate for the protective efficacy of vaccines [52,53].
The cross-reactive nature of IgG antibodies against the heterol-
ogous ayw serotype supports the idea that immunization with one
of HBsAg serotypes may produce IgG response broadly reactive
with HBsAg epitope variants. This could be of importance for the
protective immunity against various serotypes of HBV.
In these studies nasal immunization with HBsAg-NE also
induced significant mucosal immunity as documented by IgA and
IgG detected in BAL fluids, although the role of mucosal IgA in
protecting from a blood-borne pathogen like HBV is not clear.
Mucosal immunization with HBsAg-NE also induced antigen-
specific T cell responses similar to those reported by our group
when using NE as a mucosal adjuvant for gp120, rPA, and
vaccinia virus in various mouse strains [40,41,54]. In vitro
Figure 4. Comparison of mucosal NE-based with conventional aluminum-based injectible HBsAg vaccine. Time course of antibody
response: Mice were immunized with 20 mg HBsAg. Antigen was mixed with 20% NE for intranasal administration (HBsAg-NE), or adsorbed on
aluminum hydroxide (HBsAg-Alu) for intramuscular injections (A). Serum anti-HBsAg IgG antibody concentrations are presented as mean of endpoint
titers in individual sera +/2 SEM. * indicates a statistical difference (p value,0.05) in the anti-HBsAg IgG titers. Arrows indicate vaccine administration.
Avidity of anti-HBsAg IgG: Analysis of sera from mice immunized i.n. with HBsAg-NE and with i.m. injections of HBsAg-Alu vaccines (B). Avidity
indexes (AI) were assessed using 1.5 M NaSCN as a discriminating salt concentration. Each circle represents individual AI and lines indicate mean AI
value for each group obtained in two independent assays. Serum anti-HBsAg IgG subclass: Anti-HBsAg IgG subclass pattern in mice immunized
nasally with HBsAg-NE and injected i.m. with HBsAg-Alu vaccine (C). Analysis of sera collected at 22 weeks after initial immunization. The results are
presented as ratio of the specific subclass IgG to the overall IgG titer. * indicates statistical difference (p value,0.05) between NE-based and alum-
based immunizations.
doi:10.1371/journal.pone.0002954.g004
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HBsAg resulted in a cytokine response characterized by significant
secretion of hallmark Th1 type cytokines such as IFN-c and TNF-
a, while Th2 type cytokines IL-4, IL-5 and IL-10 showed no
antigen-specific response [55,56,57]. In addition to enhancing the
magnitude of antibody response, nanoemulsion adjuvant clearly
had an effect on the pattern of IgG isotypes, as indicated by
prevalence of IgG2 over IgG1 subclass in contrast to vaccination
with HBsAg-Alu which produced overwhelming titers of IgG1
antibodies [32,58]. Prevalence of IgG2b in the overall IgG
response provided additional confirmation of a Th1 bias in cellular
immunity produced by HBsAg-NE vaccination. However, it is
important to note that IgG1 still remained at significant titers,
which may suggest co-activation of both Th1 and Th2 immune
elements [59]. Although this effect resembles immunostimulation
with MPLA, CpG or the other TLR agonists, the lack of any pro-
inflammatory compound in the NE and the absence of local nasal
inflammation or irritation from the HBsAg-NE argues against
activation of these pathways [60,61]. In general, pro-inflammatory
cytokines were not detected systemically in serum with the
exception of elevated levels IL-6 up to 24 hours following
intranasal treatment with NE-HBsAg. Although the role of IL-6
in mucosal environment is fully understood, it has been shown to
be play a variety of regulatory functions in development of
immune response [62,63,64]
These studies are significant for a number of reasons. This
vaccination produced immunity to HBsAg compatible with
aluminum salt-adjuvanted vaccines, but without the need for
injection or an inflammatory adjuvant. The ability to produce this
level of serum antibodies with nasal immunization is also unique,
and shows the potential of this methodology. In addition, the
simple approach to formulation of this vaccine makes it suitable to
be produced without special equipment. These characteristics
should facilitate the use of this vaccine in developing regions of the
world. The other advantage of this formulation is its stability. Two
mechanisms (electrostatic and hydrophobic interactions) of
antigen-lipid association can be documented. The exothermic
reaction upon mixing these components also suggests that the
mixture is more stable than protein in aqueous solution. The
association of the antigen complex with NE through hydrophobic
mechanisms seems plausible given the negative change in heat
capacity (Cp) and because HBsAg particles contain ,20% host-
cell derived lipids [65,66,67]. Laser diffraction particle sizing and
zeta potential measurement indicate that cationic lipid-phase NE
droplets associate with HBsAg and remain uniform in size and
stable over a broad range of concentrations and temperature
conditions. This indicates that the physical association of HBsAg
with the lipid phase of NE provides stability to the antigen as well
as contributing to the adjuvant capability of NE. Because
maintaining cold chain conditions of 4uCt o8 uC during inventory,
storage and transport contributes significantly to the cost of the
currently licensed hepatitis B vaccines, this stability is significant.
Figure 5. Characterization of immune response mucosal and
cellular responses to HBsAg-NE. Mucosal antibody measurements
were performed in BAL fluids obtained 23 weeks after i.n immunization
with HBsAg-NE vaccines. IgA detection: The anti-HBsAg IgA detection
was performed with 1:2 dilutions of BAL (A). Results are presented as
mean values of OD at 405 nm +/2SEM. IgG detection: The anti-HBsAg
IgG antibody concentrations are presented as end point titers (B).
Antigen-specific cytokine expression. Pattern of Th1 (IFN-c and
TNF-a) and Th2 (IL-4, IL-5 and IL-10) cytokine expression in vitro in
splenocytes from mice intranasally immunized with HBsAg-NE (C).
Splenocytes were obtained at 23 weeks after initial immunization from
mice with HBsAg-20% NE. Results are presented as fold increase of the
cytokine production over levels detected in non-stimulated splenocyte
cultures.
doi:10.1371/journal.pone.0002954.g005
Figure 6. Immunogenicity in rats and guinea pigs. Rats and
guinea pigs were immunized intranasally with either 5 mgo r2 0mg
HBsAg mixed with 20% NE. Serum anti-HBsAg IgG antibody concen-
trations are presented as mean of endpoint titers in individual
sera6SEM. Data represents anti-HBsAg end titers measured 3 weeks
after a single dose (1 dose) vaccination and after two vaccinations (2
doses) measured at 7 weeks.
doi:10.1371/journal.pone.0002954.g006
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6 months at 25uC and 3 months at 40uC, the vaccine might not
require refrigeration for the final stages of distribution. At the least,
it indicates that accidental breaks in the cold chain, as often occurs
in developing countries, would not necessitate the destruction of
the vaccine. Also, the decreases in immunogenicity were readily
detected by in vitro analyses (Figure 7B and 7C), allowing for easy
evaluation of vaccine stocks.
Figure 7. In vitro analyses of HBsAg-NE stability. The comparison of HBsAg-NE stored at test temperature conditions to freshly prepared
formulation using SDS-PAGE followed by silver staining (S) or Western immunoblotting (W) is shown. Lanes are labeled according to sample storage
conditions as follows- 1: fresh, 2: 4uC, 3: 25uC and 4: 40uC. Samples were stored for (A) 6 weeks, (B) 6 months (24 weeks), or (C) 1 year (52 weeks) at
the three test temperatures. Each lane contains 0.5 mg of antigen. Arrow indicates the HBsAg major band. (D) Particle size comparison of NE alone to
freshly mixed HBsAg-NE and formulation stored up to a year. Mean diameter of particles is shown in microns +/2 SD.
doi:10.1371/journal.pone.0002954.g007
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matory substances, such as a toxin or microbiological component,
found to trigger signaling pathways and cytokine production [68].
Also, enterotoxin-based adjuvants, such as cholera toxin, have been
associated withinducinginflammationinthe nasalmucosaand with
production of the inflammatory cytokines and transport of the
vaccine along olfactory neurons into the olfactory bulbs, [69]. Some
patients treated with a flu vaccine based on one of these toxins
(Nasalflu, Berna Biotech), developed Bell’s palsy [70] presumably
due to the vaccine in the olfactory bulb. This finding led to Nasalflu
being withdrawn, and it is unclear whether other mucosal vaccines
using this approach will be acceptable for humans. Our studies
indicate no significant inflammation in HBsAg-NE treated animals
and there was no evidence of the vaccine in the olfactory bulb.
These finds are encouraging and suggest that successfully nasal
mucosal adjuvant activity might be achieved without toxicity.
These studies document that HBsAg-NE is a safe and potent
mucosal adjuvant for a novel hepatitis B vaccine. Its unique
benefits include needle-free mucosal administration, induction of
systemic immunity comparable with conventional vaccines, as well
as mucosal and cellular immune responses that are not elicited by
injected, aluminum-based hepatitis vaccines. The vaccine has
stability that could improve its utility in the developing world.
Given the ability to induce potent Th1 cellular immunity, this
vaccine also may provide therapeutic benefit to patients with
chronic HBV infection who lack cellular immune responses to
adequately control the virus.
Materials and Methods
Adjuvant and antigen
Nanoemulsion (NE, W805EC formulation) was supplied by
NanoBio Corporation, Ann Arbor, MI. Nanoemulsion was
manufactured by emulsification of cetyl pyridinium chloride
(CPC, 1%), Tween 80 (5%) and ethanol (8%) in water with
soybean oil (64%) using a high speed emulsifier, with resultant
mean droplet size of less than 400 nm in diameter. W805EC is
formulated with surfactants and food substances that are
‘Generally Recognized as Safe’ (GRAS) by the FDA, and can be
economically manufactured under Good Manufacturing Practices
(GMP). The nanoemulsion is stable for at least 3 years at 25u C.
Recombinant HBs antigen adw serotype used for immunizations
(HBsAg) was supplied by Human Biologicals Institute (Indian
Immunologics, Ltd., Hyderabad, India). The antigen protein was
purified from Pichia pastoris transfected with plasmid pPIC3K using
standard methods according to Indian Immunologicals SOP and
GMP procedures. HBsAg was dissolved in PBS (pH 7.03) and
endotoxin level was determined to be ,7.5 EU/20 mg of protein;
below international standard of #30 EU/20 mg of protein.
General reagents
Phosphate buffered saline (16PBS and 106PBS, pH 7.4) was
purchased from Cellgro (Medtech, Inc). Deionized water was
prepared using a Milli-QH Ultrapure Water Purification system
(Millipore, Billerica, MA). The bovine serum albumin (BSA) was
purchased from Sigma. Alkaline phosphatase (AP) conjugated
rabbit anti-mouse IgG (H&L), IgG1, IgG2a, IgG2b, IgG3, IgA (a
chain specific), goat anti-rat IgG (H&L), and goat anti-guinea pig
IgG (H&L) secondary antibodies were purchased from Rockland
Immunochemicals, Inc.
Particle sizing studies
HBsAg-NE formulations were prepared by vigorously mixing
concentrated NE with HBsAg and PBS. Mixtures contained a final
Figure 8. In vivo analyses of HBsAg-NE stability. HBsAg specific
antibody responses to freshly prepared HBsAg-NE or HBsAg-NE stored
under real-time (4uC), accelerated (25uC) and stressed (40uC) temper-
ature conditions are depicted. CD-1 mice were vaccinated with either
freshly prepared or stored HBsAg-NE and boosted at 6 weeks. Serum
anti-HBsAg IgG antibody concentrations are presented as a mean of
endpoint titers in individual sera +/2 SD. Comparison of serum IgG
elicited by freshly prepared HBsAg-NE to formulation stored for (A)
6 weeks, (B) 3 months, (C) 6 months or (D) 1 year at indicated
temperatures. * indicates a statistical difference (p value,0.05) in the
anti-HBsAg IgG titers between freshly mixed and stored formulation.
Arrows indicate vaccine administration.
doi:10.1371/journal.pone.0002954.g008
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1%, 20%, or 40% (v/v) NE concentrations and normalized to
16PBS.
The lipid-phase NE droplets were sized by quasi-elastic light
scattering using an LS230 instrument (Beckmann-Coulter, Full-
erton, CA) following manufacturer’s protocols. In brief, between
10 ml and 30 ml of NE-antigen mixtures were diluted into a flow
chamber containing 1 L of deionized water. Particle size
distributions were calculated using number weighting, and
statistics were generated from the average of three 60 second
measurement cycles. Sample concentration was optimized based
on PIDS obscuration, and PIDS data was included in the
instrument’s Fraunhofer model calculation.
HBsAg analysis
The integrity of HBsAg protein was analyzed using sodium
dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and Western blotting techniques. HBsAg was mixed in 20% NE at
0.5 mg/ml and 2.5 mg/ml concentrations. Aliquots of each of the
HBsAg-NE mixtures were incubated at 4uC, 25uC and 40uC for
up to 72 hrs. For PAGE analysis, the HBsAg samples were
resuspended in 1% SDS, reduced with b-mercaptoethanol (BME,
2.5%) and boiled for 15 minutes. The electrophoresis was
performed in duplicates using 0.5ug HBsAg, 4–12% Bis-Tris
PAGE gels (Invitrogen), and MES SDS Running Buffer. One gel
of each duplicate was stained using the SilverQuest Silver Staining
Kit (Invitrogen). For Western blots, gels were transferred onto
Immobilon-P PVDF membrane (Millipore) in NuPAGE transfer
buffer according to Invitrogen’s protocol. The membranes were
blocked for 1 hr in 5% Milk/PBST and were probed with a
polyclonal goat anti-HBsAg (Abcam). Alkaline phosphatase-(AP)
conjugated anti-goat (Sigma) secondary antibodies were used with
1-Step NBT/BCIP AP substrate (Pierce) for protein detection.
Zeta potential measurment
Zeta potential measurements were obtained using a NI-
COMP
TM 380ZLS (PSS.NICOMP, Santa Barbara, CA). Samples
containing 20% NE mixed with 2.5 mg/ml HBsAg were prepared
by vigorously mixing concentrated NE and HBsAg. Test mixtures
were diluted in either PBS or de-ionized water. Zeta potential was
measured in 2006diluted samples at 25uC.
Isothermal titration calorimetry
The interaction of the amphiphilic HBsAg with the lipid phase
of NE was studied using an isothermal titration microcalorimeter
Figure 9. Histopathological analysis of nasal tissue exposed to
NE adjuvant or HBsAg-NE. Mice: CD-1 mice were vaccinated with
HBsAg-NE and primed at 2 weeks. (A–B) Photomicrographs of H&E
stained nasal epithelium collected from mice 14 days following the
boost vaccination. Only normal tissue architecture was recorded which
indicates a lack of (sub) chronic cytotoxicity or inflammation. (C) Nasal
epithelium collected 24 hours following boost vaccination with HBsAg-
NE scored as a +1 grade change according to methodology as
described is shown as an example of architectural change. The arrow
indicates a single microscopic focus of accumulation of mucoid material
and debris in the nasal passages. However, no evidence of epithelial
necrosis or inflammatory infiltration of the nasal epithelium is detected.
(D) Nasal epithelium collected 24 hours following boost vaccination
with HBsAg-NE scored as a +2 grade. The arrow indicates a single
microscopic focus of accumulation of mucoid material and debris in the
nasal passages in the absence of inflammatory changes. Architectural
change demonstrated in C and D are considered incidental and can be
observed in non-vaccinated mice. Rats and guinea pigs: Nasal
epithelium was collected 14 days following final boost vaccination from
rats (E–F) and guinea pigs (G–H) treated a total of 3 doses of HBsAg-NE
administered 14 days apart. Normal tissue architecture is observed
suggesting lack of toxicity or inflammation. Dogs: Nasal biopsies were
collected 24 hours following the final dose in dogs treated with a total
of three doses of NE adjuvant. NE was delivered using a Pfeiffer
multidose wide angle sprayer pump in 200 ml/dose (I) or 400 ml/dose (J).
No evidence of inflammation or cytotoxicity was detected.
doi:10.1371/journal.pone.0002954.g009
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TM). HBsAg solutions in
PBS aliquots were prepared from concentrated stock and
introduced into the calorimetric reaction and reference vessels
(1.3 ml). Chambers were then gently agitated until temperature
equilibrium with the surroundings was reached. Concentrated NE
(50% wt) was diluted in PBS to 1% (v/v). After the sample vessel
had reached the equilibrium conditions, the NE solution was
added in discrete injections using a syringe, into the calorimetric
reaction vessel under continuous stirring (either 30uCo r4 0 uC).
The experimentally observed change of energy corresponding to a
given injection of NE was measured and plotted using software
(Origin 7SR4 v. 7, Origin Lab Corp., Northhampton, MA). The
change in heat capacity of binding (DCp) was calculated using the
following equation: DCp=(DHuT2-DHuT1)/T2-T1 where DHi s
calculated enthalpy and T is vessel temperature [71].
Preparation of HBsAg-NE vaccine
HBsAg-NE formulations were prepared 30 to 60 minutes prior
to immunization by vigorously mixing HBsAg protein solution
with concentrated NE using PBS as diluent. For intranasal
immunizations HBsAg-NE doses ranged from 1 mgt o4 0 mg
HBsAg mixed with 5% to 40% NE. For intramuscular
immunizations with the HBsAg/aluminum hydroxide vaccine
(HBsAg-Alu), antigen was adsorped onto 0.5 mg/ml aluminium
hydroxide (Sigma) following the adsorption procedure described in
[72] to obtain formulation similar to that of EngerixH (Glax-
oSmithKline).
Animals
Pathogen-free, outbred CD-1 mice (females 6–8 weeks old),
inbred BALB/c mice (females 6–8 weeks old), and Hartley guinea
pigs (females 10–11 weeks old) were purchased from Charles River
Laboratories. Pathogen free Sprague Dawley rats (females 7–
8 weeks old) and specific pathogen free (SPF) purpose-bred
American standard beagles (females, 6 month old) were obtained
from Harlan and Covance, respectively. Animals used in these
studies were housed in SPF conditions with food and water
available ad libitum in accordance to the standards of the
American Association for Accreditation of Laboratory Animal
Care. Mice were housed with 5 to a cage. Rats and guinea pigs
were housed 3 to a cage. Dogs were housed in floor pens with soft
bedding and in a rotating group setting. Daily exercise was
provided as enrichment. All procedures performed on animals
within this study were conducted in accordance with and by
approval of the University of Michigan University Committee on
Use and Care of Animals (UCUCA).
Immunization procedures
CD-1 mice (n=5 per group for immunogenicity studies,
n=10 per group for stability studies) were vaccinated with
two administrations of HBsAg-NE vaccine six weeks apart.
Both intranasal (i.n.) and intramuscular (i.m.) immunizations
were performed in mice anaesthetized with isoflurane using
IMPAC 6H anesthesia delivery system. For i.n. administration,
animals were held in a supine position and 8 ml( 4ml/nare) of
HBsAg-NE vaccine was administered slowly to the nares using
a micropipette tip. For i.m. immunization, the 50 mlo f
HBsAg-Alu vaccine was injected into apaxial muscle. Rats,
and guinea pigs (n=5 per group) were also manually
restrained in a supine position and 100 ml (50 ml/nare) of
HBsAg-NE vaccine was administered slowly to the nares using
a micropipette tip.
Table 2. Pre-clinical toxicology evaluation.
Species/Strain
a Treatment
Number of
Dose
Dose Volume
(ul) Group Average Histopathological Score
b Metabolic
Analysis
d
NE (%) HBsAg (ug) Nasal Pulmon. Brain Other
c
Mouse/CD-1 0 20 2
e 10 0 0 0 0 n/a
12 0 2
e 10 0 0 0 0 n/a
52 0 2
e 10 1.060.9 0 0 0 n/a
10 20 2
e 10 0.761.1 0 0 0 n/a
20 20 2
e 10 1.461.3 0 0 0 n/a
20 0 2
e 10 1.161.7 0 0 0 n/a
Mouse/BALB/c 20 0 4
f 61 . 2 60.4 0 0 0 n/a
20 0 7
g 62 . 0 61.0 0 0 0 n/a
Rat/Wistar 20 32 3
h 20 0 0 0 0 Normal
Guinea Pig/Hartley 20 32 3
h 20 0 0 0 0 Normal
Canine/Beagle 20 0 3
e 200 0 n/a n/a n/a Normal
20 0 3
e 400 0 n/a n/a n/a Normal
a- The number of animals used for analysis: CD-1 (n=10), BALB/c, Wistar rats and Hartley guinea pigs (n=5) and Beagles (n=1) per group.
b- Histological lesions were evaluated on a scale from 0 to 10 with +1 single microscopic focus, +2 at least 2 microscopic foci, +3 more than 3 foci or multiple locally
extensive areas of pathology, +4t o+6 were associated increasing severity and more extensive distribution (these lesions could be associated with morbidity), +7a n d
above had increasing degrees of inflammation (+10 associated with mortality).
c- Other tissues evaluated include heart, liver, kidneys, spleen, esophagus, trachea, stomach, intestines, pancreas, and adrenals.
d- Metabolic analysis evaluated by standard biochemical serum profile analysis on a IDEXX Vet Test Analyzer
TM and performed at the Animal Diagnostic Laboratory
through the Unit for Laboratory Animal Medicine at the University of Michigan. Normal indicates all analytes fell within normal expected distributions per species.
e- Administered every 2 weeks.
f- Administered every 15 minutes.
g- Administered every 4 hours.
h- Administered every 4 weeks.
doi:10.1371/journal.pone.0002954.t002
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collection
Blood samples were obtained from the saphenous vein in mice,
rats, and guinea pigs and from the superficial cephalic vein in dogs
at various time points during the course of the experiments. The
terminal murine sample was obtained by cardiac puncture post-
euthanasia. Serum was separated from whole blood by centrifu-
gation at 15006g for 5 minutes after allowing coagulation for 30
to 60 minutes at room temperature. Serum samples were stored at
220uC until analyzed.
Bronchioalveolar lavage (BAL) fluid was obtained from mice
euthanized by an overdose of isoflurane. A 22 gauge catheter
(Angiocath, B-D) attached to a syringe was inserted into the distal
trachea. The lungs were infused twice with 0.5 ml of PBS
containing 10 mM DTT and 0.5 mg/ml aprotinin and approxi-
mately 1 ml of aspirate was recovered. BAL samples were stored at
220uC until analyzed.
At the time of euthanasia, spleens were harvested from mice and
mechanically disrupted to obtain single-cell splenocyte suspension
in PBS, which was used for in vitro determination of cytokine
response. Red blood cells were removed by lysis with ACK buffer
(150 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA), and the
remaining cells were washed twice in PBS. For the cytokine
expression assays, splenocytes were resuspended in RPMI 1640
medium supplemented with 2% FBS, 200 nM L-glutamine, and
penicillin/streptomycin (100 U/ml and 100 mg/ml).
Determination of IgG and IgA antibodies in serum and
BAL fluid
Mouse, rat, and guinea pig anti-HBsAg specific IgG and mouse
anti-HBsAg specific IgA levels were determined by ELISA.
Microtiter plates (NUNC) were coated with 5 mg/ml (100 ml) of
HBsAg in a coating buffer (50 mM sodium carbonate, 50 mM
sodium bicarbonate, pH 9.6) and incubated overnight at 4uC. The
protein solution was removed and plates were incubated with
blocking buffer (PBS with 1% dry milk) for 30 minutes at 37uC.
After the blocking solution was aspirated, the plates were used
immediately or stored sealed at 4uC until needed. For antibody
detection, serum and BAL samples were serially diluted in 0.1%
BSA in PBS. The 100 ml/well aliquots were incubated in HBsAg
coated plates for 1 hour at 37uC. Plates were washed three times
with PBS containing 0.05% Tween 20, followed by 1 hour
incubation with either species specific anti-IgG or IgA alkaline
phosphatase (AP)-conjugated antibodies, then washed three times
and incubated with AP substrate Sigma Fast
TM (Sigma). The
colorimetric reaction was stopped with 1 N NaOH according to
the manufacturer’s protocol, and optical density (OD) measured
using a Spectra Max 340 ELISA reader (Molecular Devices,
Sunnyvale, CA) at 405 nm and the reference wavelength of
690 nm. The antibody concentrations are presented as endpoint
titers defined as the reciprocal of the highest serum dilution
producing an OD above cutoff value. The cutoff value is
determined as OD of the corresponding dilution of control sera+2
(standard deviations) and plate background [73,74]. Normaliza-
tion of IgG was performed at UMHHC diagnostic laboratory
using an ADVIA Centaur anti-HBsAg assay.
Determination of IgG avidity
The avidity index (AI) was determined by ELISA using mouse
serum as described by Vermont et al. [75] with minor
modifications. Sodium thiocyanate (NaSCN) was used for
dissociation of low avidity antibody-antigen binding. Optimal
assay conditions for determination of AI were established in an
ELISA assay using 0 M to 3 M range of NaSCN concentrations.
We have identified that incubation with 1.5 M NaSCN solution
resulted in reduction of antibody binding that was discriminating
between serum samples. In each assay, serial dilutions of immune
serum were incubated with HBsAg as described above for
standard ELISA. To differentiate antibody binding, the wells
were incubated with either PBS or with 1.5 M NaSCN at room
temperature for 15 minutes. Subsequently wells were washed
three times and incubated with anti-mouse IgG AP-conjugate as
described above. The AI was calculated as percentage of antibody
titer which remained bound to antigen after incubation with
NaSCN in comparison to the standard ELISA protocol.
Luminex analysis of cytokine expression
Freshly isolated mouse murine splenocytes were seeded at
4610
6 cells/ml (RPMI 1640, 2% FBS) and incubated with HBsAg
(5 mg/ml) or control PHA-P mitogen (2 mg/ml) for 72 hours.
Serum and cell culture supernatants were harvested and analyzed
for the presence of cytokines. These assays were performed using
LuminexHMultiplex21 multi-analyte profiling beads (Luminex
Corporation, Austin, TX), according to the manufacturer’s
instructions.
Analyses of thermostability of HBsAg-NE
For vaccine thermostability studies, the formulation was made
by vigorously mixing HBsAg and NE to achieve a dose of 2.5 mg/
ml recombinant protein in 20% NE and a final buffered solution
of 16PBS. The vaccine was then aliquoted into sterile glass vials
with Teflon-coated caps (Wheaton) and stored at either 462uC,
2562uCo r4 0 62uC. Temperatures were monitored for the period
of the study by Lufft OPUS10 thermographs (PalmerWahl). At
time points of 6 weeks, 12 weeks (3 months), 24 weeks (6 months)
and 52 weeks (1 year), an aliquot was withdrawn and used for in
vitro as well as in vivo analyses. For in vitro analyses 0.5 mgo f
antigen contained in vaccine product was electrophoresed per lane
and detected by silver staining and Western blotting (as described
above); NE particle size was also determined (as described above).
In vivo immunogenicity studies were done by intranasal
vaccinations (primed at 0 and boosted at 6 weeks) of about
8 week old female CD-1 mice (n=10 per group) and testing serum
IgG titers at 2, 3, 5, 8, 10 and 12 weeks as described above.
Comprehensive toxicity assessments
Acute and (sub) chronic toxicity responses to either NE or
HBsAg-NE were assessed in mice, rats, guinea pigs, and dogs. We
have evaluated numerous species in order to minimize the effects
of animal model biasing. The end points of the study were
histopathological evaluation of exposed tissues and of highly
perfused organs. Metabolic changes were also measured using
serum biochemical profile analysis.
The clinical status of each animal including the nasal cavity,
body weight, body temperature, and food consumption was
assessed throughout the study. Mice were non-surgically implanted
with programmable temperature transponders (IPTT-3000, Bio
Medic Data Systems, Inc.) for non-invasive subcutaneous
temperature measurement with a handheld portable scanner
(DAS-6002, Bio Medic Data Systems, Inc.). Euthanasia by
isoflurane asphyxiation was performed in mice whereas rats and
guinea pigs were euthanized by barbiturate overdose. A complete
necropsy, which included the gross pathological examination of
the external surface of the body, all orifices, and the cranial
thoracic and abdominal cavities and their contents, was performed
on all rodent species at the time of death. Vaccine exposed tissues
and highly perfused organs including the sinus cavity, lungs,
A Novel Nasal HBV Vaccine
PLoS ONE | www.plosone.org 12 August 2008 | Volume 3 | Issue 8 | e2954esophagus, trachea, brain, heart, liver, kidneys, spleen, stomach,
intestines, pancreas, and adrenals were collected and immediately
fixed in 10% buffered formalin (Fisher Scientific).
In order to assess safety and tolerability of the adjuvant, NE was
delivered to dogs using a wide angle nasal sprayer pump (Pfeiffer
62602, 415 screw enclosure). The containers used were Saint
Gobain Desqueres 5-mL U-Save
TM Type 1 amber glass bottles
with a 415 neck finish. The dose volume for the sprayer pump was
100 ml. Dogs received either 200 ml (100 m/nare) or 400 ml
(200 ml/nare) administered every 14 days for a total of 3 doses
as outlined in Table 2. Rostral nasal sinus punch biopsy samples
were collected 24 hours following the final treatment. For the
biopsy procedure, dogs were anesthetized with ketamine/diaze-
pam/butorphanol (10 mg/kg, 0.5 mg/kg, 3 mg/kg) and main-
tained on 2.5% isoflurane after endotracheal intubation. The
anterior sinus cavity and external nares were sterilely prepared. A
sterile dermal punch biopsy instrument (Miltex, 4 mm) was
introduced approximately 1.5 cm into ventral portion of the
anterior sinus cavity. Hemostasis was achieved using 4-0 PDS
suture material. Tissues obtained for biopsy were immediately
fixed in 10% buffered formalin (Fisher Scientific). Butorphanol
(3 mg/kg) administration was continued every 8 hours for three
days following the biopsy procedure for analgesic management.
Histopathological analysis
Harvested tissues were fixed in 10% formalin solution for at
least 24 hours. Sinus tissues including bone were decalcified for
48 hours using Cal-EX
TM II (Fisher Scientific) prior to trimming
and embedding in paraffin. For mice, rats, and guinea pigs, four
standard cross sections of the nasal passages including the brain
were taken [76]. Tissue blocks were processed in xylene and
paraffin embedded for multi-sections and slide preparation.
Routine hematoxylin and eosin (H&E) staining of each slide was
carried out and blindly examined by a veterinary pathologist.
Histopathological lesions were scored on a histological grading
scale ranging from 0 to 10 based on severity and distribution.
The histopathology of the nasal cavity was scored using very
strict criteria. Any finding other than pristine was given a positive
score. A single small focus of accumulation of amorphous material
and/or the presence of any cell damage no matter how slight was
scored as +1( Figure 9C). More than one focus of accumulation of
material and/or cell damage was scored as +2( Figure 9D). More
than 3 foci of accumulation of material and/or cell damage or
multiple locally extensive areas of pathology were scored as +3.
The lesions graded as +4t o+6 were associated with increasing
severity and more extensive distribution of lesions including the
presence of lesions in more than one section. These lesions could
be associated with morbidity. The +7 and above had increasing
degrees of inflammation. Mortality would be given a score of +10.
Hematological and serum biochemical profile analysis
Whole blood samples were collected from rats and guinea pigs
2 weeks following the final vaccine dose. Dogs were phleboto-
mized every 14 days and at the study termination at day 43. A
portion of the blood was placed in Vacutainer
TM tubes containing
EDTA (BD) and a portion was placed in serum separator
Vacutainer
TM tubes (BD). Anti-coagulated blood was processed
to determine hematological parameters (lymphoyctes, monocytes,
eosinophils, basophils, red blood cells, hemoglobin , hematocrit,
mean corpuscular hemoglobin, mean corpuscular volume, mean
corpuscular hemoglobin concentration, and platelets) in a
HEMAVETH 950 hematology analyzer (Drew Scientific, Inc.,
Oxford, CT) in accordance to manufacturer’s recommendation.
Hematological data was compared to species laboratory reference
values as established by the Animal Diagnostic Laboratory at the
University of Michigan.
Serum samples were analyzed using a VetTest Chemistry
AnalyzerH (Idexx, Westbrook, Maine). A complete chemistry
panel including albumin, alkaline phosphatase, alanine amino-
transferase, amylase, aspartate aminotransferase, total calcium,
total cholesterol, creatinine, glucose, phosphorous, total bilirubin,
total protein, blood urea nitrogen, sodium, potassium, chloride,
globulin, and creatine kinase was performed. Biochemical data
was compared to species laboratory reference values as established
by the Animal Diagnostic Laboratory at the University of
Michigan.
Statistical Analysis
Results are expressed as mean6standard error of the mean
(SEM) or6standard deviation (SD). Statistical significance was
determined by ANOVA (analysis of variance) using the Student t
and Fisher exact tests or a Bonferroni’s Multiple comparison
analysis. The analyses were done with 95% confidence limits and
two-tailed tests. A p value,0.05 was considered to be statistically
significant.
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